NCT05230810 2026-03-16
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
Criterium, Inc.
Phase 1/2 Active not recruiting
Clinical Trials
3 trialsNCT04778982 2023-07-17
Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Terminated
NCT04385563 2020-05-13
A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Unknown